Nerve growth factor (NGF): A potential urinary biomarker for overactive bladder syndrome (OAB)?

BJU International

Volumn 111, Issue 3, 2013, Pages 372-380

  Seth, Jai H ^a   Sahai, Arun ^b   Khan, Mohammad S ^b   Van Der Aa, Frank ^c   De Ridder, Dirk ^c   Panicker, Jalesh N ^a   Dasgupta, Prokar ^b   Fowler, Clare J ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

biomarker; nerve growth factor; overactive bladder

Indexed keywords

BIOLOGICAL MARKER; BOTULINUM TOXIN A; BRAIN DERIVED NEUROTROPHIC FACTOR; CREATININE; MESSENGER RNA; MUSCARINIC RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; PROSTAGLANDIN E2; SOLIFENACIN;

BLADDER NECK STENOSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYSTALGIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERSTITIAL CYSTITIS; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; NONHUMAN; NORMAL VALUE; OVERACTIVE BLADDER; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN URINE LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; SYSTEMATIC REVIEW; TISSUE LEVEL; URINE INCONTINENCE;

ANIMALS; BIOLOGICAL MARKERS; BOTULINUM TOXINS, TYPE A; CATS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MICE; MUSCARINIC ANTAGONISTS; NERVE GROWTH FACTOR; NEUROMUSCULAR AGENTS; RATS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 84874594453     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11672.x     Document Type: Review

References (50)

1. Levi-Montalcini R, Calissano P,. The nerve-growth factor. Sci Am 1979; 240: 68-77
2. Ochodnicky P, Cruz CD, Yoshimura N, Michel MC,. Nerve growth factor in bladder dysfunction: Contributing factor, biomarker, and therapeutic target. Neurourol Urodyn 2011; 30: 1227-1241
3. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-178
4. Liu HT, Chancellor MB, Kuo HC,. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 2009; 56: 700-706
5. Michel MC, Chapple CR,. Basic mechanisms of urgency: roles and benefits of pharmacotherapy. World J Urol 2009; 27: 705-709
6. Liu HT, Chen CY, Kuo HC,. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders. J Formos Med Assoc 2010; 109: 862-878
7. Birder LA, Wolf-Johnston AS, Chib MK, Buffington CA, Roppolo JR, Hanna-Mitchell AT,. Beyond neurons: Involvement of urothelial and glial cells in bladder function. Neurourol Urodyn 2010; 29: 88-96
8. Vizzard MA,. Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol 2000; 161: 273-284
9. Hu VY, Zvara P, Dattilio A, et al. Decrease in bladder overactivity with REN1820 in rats with cyclophosphamide induced cystitis. J Urol 2005; 173: 1016-1021
10. Ho DR, Chen CS, Lin WY, Chang PJ, Huang YC,. Effect of hyaluronic acid on urine nerve growth factor in cyclophosphamide-induced cystitis. Int J Urol 2011; 18: 525-531
11. Yoshimura N, Bennett NE, Hayashi Y, et al. Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. J Neurosci 2006; 26: 10847-10855
12. Schnegelsberg B, Sun TT, Cain G, et al. Overexpression of NGF in mouse urothelium leads to neuronal hyperinnervation, pelvic sensitivity, and changes in urinary bladder function. Am J Physiol Regul Integr Comp Physiol 2010; 298: R534-547
13. Lee SR, Hong CH, Choi YD, Kim JH,. Increased urinary nerve growth factor as a predictor of persistent detrusor overactivity after bladder outlet obstruction relief in a rat model. J Urol 2010; 183: 2440-2444
14. Zvara P, Kliment J, Jr, DeRoss AL, et al. Differential expression of bladder neurotrophic factor mRNA in male and female rats after bladder outflow obstruction. J Urol 2002; 168: 2682-2688
15. Ha US, Park EY, Kim JC,. Effect of botulinum toxin on expression of nerve growth factor and transient receptor potential vanilloid 1 in urothelium and detrusor muscle of rats with bladder outlet obstruction-induced detrusor overactivity. Urology 2011; 78: 721 e1-7216
16. Seki S, Sasaki K, Fraser MO, et al. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol 2002; 168: 2269-2274
17. Seki S, Sasaki K, Igawa Y, et al. Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. J Urol 2004; 171: 478-482
18. Giannantoni A, Di Stasi SM, Nardicchi V, et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006; 175: 2341-2344
19. Liu HT, Kuo HC,. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 2007; 70: 463-468
20. Lowe EM, Anand P, Terenghi G, Williams-Chestnut RE, Sinicropi DV, Osborne JL,. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol 1997; 79: 572-577
21. Henry JL,. Substance P and inflammatory pain: potential of substance P antagonists as analgesics. Agents Actions Suppl 1993; 41: 75-87
22. Kuo HC, Liu HT, Chancellor MB,. Can urinary nerve growth factor be a biomarker for overactive bladder? Rev Urol 2010; 12: e69-77
23. Mayeux R,. Biomarkers: potential uses and limitations. NeuroRx 2004; 1: 182-188
24. Kuo HC, Liu HT, Chancellor MB,. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodyn 2010; 29: 482-487
25. Liu HT, Chancellor MB, Kuo HC,. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int 2008; 102: 1440-1444
26. Liu HT, Lin H, Kuo HC,. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. Neurourol Urodyn 2011; 30: 1525-1529
27. Liu HT, Chancellor MB, Kuo HC,. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int 2009; 103: 1668-1672
28. Mukerji G, Yiangou Y, Grogono J, et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 2006; 176: 367-373
29. Jacobs BL, Smaldone MC, Tyagi V, et al. Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. Can J Urol 2010; 17: 4989-4994
30. Okragly AJ, Niles AL, Saban R, et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J Urol 1999; 161: 438-441; discussion 41-2
31. Liu HT, Kuo HC,. Increased urine and serum nerve growth factor levels in interstitial cystitis suggest chronic inflammation is involved in the pathogenesis of disease. PLoS One 2012; 7: e44687
32. Apostolidis A, Jacques TS, Freeman A, et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 2008; 53: 1245-1253
33. Clemow DB, Steers WD, Tuttle JB,. Stretch-activated signaling of nerve growth factor secretion in bladder and vascular smooth muscle cells from hypertensive and hyperactive rats. J Cell Physiol 2000; 183: 289-300
34. Liu HT, Kuo HC,. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. Neurourol Urodyn 2009; 28: 78-81
35. Liu HT, Kuo HC,. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology 2008; 72: 104-108; discussion 8
36. Steers WD, Creedon DJ, Tuttle JB,. Immunity to nerve growth factor prevents afferent plasticity following urinary bladder hypertrophy. J Urol 1996; 155: 379-385
37. Liu HT, Liu AB, Chancellor MB, Kuo HC,. Urinary nerve growth factor level is correlated with the severity of neurological impairment in patients with cerebrovascular accident. BJU Int 2009; 104: 1158-1162
38. Bonini S, Lambiase A, Angelucci F, Magrini L, Manni L, Aloe L,. Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma. Proc Natl Acad Sci U S A 1996; 93: 10955-10960
39. Serrano-Sanchez T, Robinson-Agramonte MA, Lorigados-Pedre L, Diaz-Armesto I, Gonzalez-Fraguela ME, Dorta-Contreras AJ,. [ Endogenous nerve growth factor in patients with Alzheimer s disease ]. Rev Neurol 2001; 32: 825-828
40. Bruns DE,. The STARD initiative and the reporting of studies of diagnostic accuracy. Clin Chem 2003; 49: 19-20
41. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 2003; 49: 1-6
42. Antunes-Lopes T, Pinto R, Barros SC, et al. Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J Urol 2013; 189: 359-365
43. Pinto R, Lopes T, Frias B, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 2010; 58: 360-365
44. Liu HT, Chen CY, Kuo HC,. Urinary nerve growth factor in women with overactive bladder syndrome. BJU Int 2011; 107: 799-803
45. Liu HT, Tyagi P, Chancellor MB, Kuo HC,. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int 2009; 104: 1476-1481
46. Liu HT, Tyagi P, Chancellor MB, Kuo HC,. Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 2010; 106: 1681-1685
47. Yokoyama T, Kumon H, Nagai A,. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol Urodyn 2008; 27: 417-420
48. Liu HT, Kuo HC,. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 2008; 179: 2270-2274
49. Kim JC, Park EY, Seo SI, Park YH, Hwang TK,. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 2006; 175: 1773-1776; discussion 6
50. Kim JC, Park EY, Hong SH, Seo SI, Park YH, Hwang TK,. Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. Int J Urol 2005; 12: 875-880